#NewAseBioMember | “#NewAseBioMember | “AseBio is the meeting point for all companies that aim to contribute to science through the biotechnology sector””

AseBio. What does your company's work bring to the table and what is its strength?

Claudio Hidalgo Cantabrana. Microviable Therapeutics is a biotech company, incorporated as a spinoff from IPLA-CSIC, developing novel biological medicines for oncology and infectious diseases. Our drugs are based on bacteria from the microbiome that can be deployed as bacterial immunotherapies obtaining great results that are not possible with other drugs.

AseBio. What is AseBio for you

Claudio Hidalgo Cantabrana. AseBio is the national force of the biotech sector and a meeting point for all the national companies that use innovation as the engine of their developments.

AseBio. When did you first hear about AseBio?

Claudio Hidalgo Cantabrana. I know about AseBio time ago and I have seen its growth and consolidation so know it is a good moment to join the organization. We will contribute with our experience in drug development to the different work task groups while learning from our new neighbours.

AseBio. What do you expect from being part of an association like AseBio?

Claudio Hidalgo Cantabrana. We expect a higher connection with the different biotec companies in Spain, join forces to fight for common interests and bottlenecks, while contributing to showcase the relevance of science and innovation to our society.

AseBio. What is the biggest challenge facing the biotech sector or your company?

Claudio Hidalgo Cantabrana. As a biotech company developing novel medicines, there are a lot of challenges but the two most important are regulatory and financing, on top of the scientific and clinical validation of the results of our developments.